The Supreme Court has issued a temporary stay on a recent ruling by the Fifth Circuit that would have banned telemedicine prescriptions for the abortion medication mifepristone. Justice Samuel Alito provided the administrative stays for cases involving Danco Laboratories, the brand-name manufacturer, and GenBioPro, a generic producer. This decision pauses the lower court’s order until May 11, while the parties involved are required to submit their responses by May 7. The ruling effectively reinstates the status quo, enabling telemedicine prescriptions and mail distribution of mifepristone to continue for now (Jurist).
This procedural move by the Supreme Court is not a determination on the merits of the case but rather allows the justices time to deliberate on whether further intervention is necessary. At the heart of the legal conflict is a 2023 Food and Drug Administration (FDA) rule intended to facilitate access to mifepristone by permitting remote prescriptions and mail dispensing—a policy initially established during the COVID-19 pandemic. However, the rule faced challenges under the Administrative Procedure Act, as opponents like Louisiana argue that the FDA relied on flawed or incomplete data in eliminating the requirement for an in-person provider visit (New York Times).
A unanimous decision by a three-judge panel of the Fifth Circuit supported Louisiana’s stance, predicting potential success on the merits and ordering a hold on the FDA rule nationwide while the legal proceedings continue. The court remarked on procedural deficits and a lack of adequate consideration acknowledged by the FDA in its own review. This ongoing battle is significant as mifepristone now accounts for over 60% of abortions in the United States, with similar legal challenges unfolding in other federal courts (Reuters).
The next critical juncture for the Supreme Court arrives on May 11, at which time the justices must decide whether to allow the Fifth Circuit’s decision to take effect, extend the current hold, or provide a more prolonged stay amid the ongoing legal dispute. The outcome carries substantial implications for abortion access and the regulation of telehealth practices across the nation.